Marcia Snodgrass
Women's Health · Dodge City, KSNPI 1184617011
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,170 and has fallen 58.2% since, to $489 in 2025. Among women's health clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$637
- AbbVie$470
- AstraZeneca$371
- Amgen$349
- Novo Nordisk$244
- Boehringer Ingelheim$212
- plus $969 from 21 others
What the payments were for
- Food & beverage$3,252100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 51 | $637 |
| AbbVie | 34 | $470 |
| AstraZeneca | 17 | $371 |
| Amgen | 23 | $349 |
| Novo Nordisk | 26 | $244 |
| Boehringer Ingelheim | 12 | $212 |
| Aimmune Therapeutics, Inc. | 6 | $145 |
| Dexcom, Inc. | 7 | $142 |
| Nestle Healthcare Nutrition Inc. | 5 | $101 |
| Xeris Pharmaceuticals, Inc. | 5 | $90 |
| Sanofi-aventis U.S. LLC | 5 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Bayer | 3 | $49 |
| Abbott | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $29 |
| Insulet Corporation | 1 | $28 |
| Organogenesis Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Biogen | 1 | $19 |
| Medtronic | 1 | $16 |
| Pfizer | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Novartis | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
| Genentech USA, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,252 in reported general payments places this provider in the 95th percentile of 43 women's health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $123,728 |
| Humira PenAdalimumab | 11 | $72,368 |
| JardianceEmpagliflozin | 38 | $40,610 |
| MounjaroTirzepatide | 35 | $35,460 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $32,151 |
| RybelsusSemaglutide | 17 | $30,136 |
| CreonLipase/Protease/Amylase | 24 | $22,527 |
| FarxigaDapagliflozin Propanediol | 13 | $19,086 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $16,886 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 423 | $15,622 |
| GemtesaVibegron | 14 | $12,124 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $10,195 |
| XareltoRivaroxaban | 15 | $9,823 |
| Oxycodone Hcl | 417 | $9,098 |
| EliquisApixaban | 14 | $8,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $244 | $153,863122 claims |
| Boehringer IngelheimJardiance | $212 | $40,61038 claims |
| Lilly USA, LLCMounjaro | $637 | $35,46035 claims |
| AbbVieCreon | $470 | $22,52724 claims |
| AstraZenecaFarxiga | $371 | $19,08613 claims |
| PfizerEliquis | $15 | $8,09314 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $33 | $1,49722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 women's health providers in Kansas.
Other women's health in Dodge City
- Stacy CorumMerriam$4K
- Julie BiermannOverland Park$3K
- Jennifer PeppardMerriam$2K
- Brandi MulryanOverland Park$2K
- Patricia ArnoldMerriam$2K
- Diane WendelkenManhattan$2K
- Jessica FergasonOverland Park$1K
- Mary LuderOverland Park$1K
- Anna GarrisonOverland Park$901
- Cindy CondrayTopeka$858
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.